Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3316531 in Healthy Subjects and Psoriasis Patients
NCT03418493Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2018
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3316531 in psoriasis (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Jan 2018; status: completed.
02
Drugs
LY3316531
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03418493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03418493.